newest glp 1 drug New GLP-1 Guidelines for Type 2 Diabetes in 2025 GLP-1 No Longer on FDA's

Tirzepatide (Mounjaro) Tirzepatide is unique because it targets two hormones: GLP-1 and glucose-dependent insulinotropic polypeptide (GIP)

It claimed 'GLP-1s for diabetes could be sold at a profit for just US $0.89 per month, compared to the price of $95 per month charged in Brazil, $115 per month charged in South Africa, $230 charged in Latvia and $353 charged in the US, which is a 39,562% markup over what the estimated generic price could be.' Christa Cepuch, Pharmacist Coordinator at MSF's Access Campaign, argues 'These new drugs are an absolute game changer for people living with diabetes, but are being kept out of the hands of hundreds of millions of people in low- and middle-income countries who need them' (Barber, Gotham, Bygrave

Perret-Guillaume C, Joly L, Benetos A

Weghuber D, Forslund A, Ahlstrom H, Alderborn A, Bergstrom K, Brunner S, et al